SBS1000
Pain (non-opioid analgesic)
Phase 1Active
Key Facts
About Sparian Biosciences
Sparian Biosciences is a privately held, clinical-stage biotech leveraging a CNS-focused drug discovery approach to develop treatments for pain and substance use disorders. Its lead asset, SBS1000, has completed Phase 1 trials, and the company has secured substantial non-dilutive funding, including over $60 million in NIH/NIDA grants. With a pipeline featuring first-in-class mechanisms for opiate and stimulant use disorders, Sparian is positioned as an innovative player in the addiction therapeutics space, though it faces the typical risks of early-stage clinical development.
View full company profile